Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 4 of 4 entries
View as:
Phase: N/A
Priority: Normal
Start: 03/30/23
End: 12/31/27
Due: 12/31/28
Phase: N/A
Priority: Normal
Start: 11/01/24
End: 12/31/28
Due: 12/31/29
Phase: N/A
Priority: Normal
Start: 01/27/25
End: 02/28/42
Due: 02/28/43
Phase: N/A
Priority: Normal
Start: 11/15/23
End: 12/15/38
Due: 12/15/39
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| SynKIR-110 for Mesothelin Expressing Ovarian Cancer, Cholangiocarcinoma or Mesothelioma | NCT05568680 | Verismo Therapeutics | user2@example.com | None | 2023-03-30 | 2027-12-31 | 2028-12-31 | - | - | 2025-07-14 |
| SynKIR-310 for Relapsed/Refractory B-NHL | NCT06544265 | Verismo Therapeutics | user2@example.com | None | 2024-11-01 | 2028-12-31 | 2029-12-31 | - | - | 2025-07-14 |
| A Long-Term Follow-Up Basket Study for Participants Treated With SynKIR Chimeric Antigen Receptor (CAR) T Cell Product | NCT06701201 | Verismo Therapeutics | user2@example.com | None | 2025-01-27 | 2042-02-28 | 2043-02-28 | - | - | 2025-07-14 |
| Long-Term Follow-Up Safety Study of Subjects Treated with SynKIR-110 in Cancer Studies | NCT06377202 | Verismo Therapeutics | user2@example.com | None | 2023-11-15 | 2038-12-15 | 2039-12-15 | - | - | 2025-07-14 |